CL2017003089A1 - Formas de dosificación sólidas de palbociclib - Google Patents

Formas de dosificación sólidas de palbociclib

Info

Publication number
CL2017003089A1
CL2017003089A1 CL2017003089A CL2017003089A CL2017003089A1 CL 2017003089 A1 CL2017003089 A1 CL 2017003089A1 CL 2017003089 A CL2017003089 A CL 2017003089A CL 2017003089 A CL2017003089 A CL 2017003089A CL 2017003089 A1 CL2017003089 A1 CL 2017003089A1
Authority
CL
Chile
Prior art keywords
dosage forms
palbociclib
solid dosage
pharmacocinetic
hydrosoluble
Prior art date
Application number
CL2017003089A
Other languages
English (en)
Inventor
Fady Makram Louiz Ibrahim
Matthew Patrick Mullarney
Ravi Mysore Shanker
Barbara Rodriguez Spong
Jian Wang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56092955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017003089(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CL2017003089A1 publication Critical patent/CL2017003089A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>FORMAS DE DOSIFICACIONES SÓLIDAS DE PALBOCICLIB QUE COMPRENDEN UN ÁCIDO HIDROSOLUBLE. LAS FORMAS DE DOSIFICACIÓN TIENEN CARACTERÍSTICAS FARMACOCINÉTICAS DESEADAS.</p>
CL2017003089A 2015-06-04 2017-12-04 Formas de dosificación sólidas de palbociclib CL2017003089A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562171177P 2015-06-04 2015-06-04
US201662332973P 2016-05-06 2016-05-06

Publications (1)

Publication Number Publication Date
CL2017003089A1 true CL2017003089A1 (es) 2018-05-11

Family

ID=56092955

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003089A CL2017003089A1 (es) 2015-06-04 2017-12-04 Formas de dosificación sólidas de palbociclib

Country Status (31)

Country Link
US (2) US11065250B2 (es)
EP (2) EP3636283A1 (es)
JP (3) JP2017002034A (es)
KR (2) KR102068423B1 (es)
CN (2) CN113616606A (es)
AU (2) AU2016272881C1 (es)
BR (1) BR112017025398A2 (es)
CA (1) CA2931892A1 (es)
CL (1) CL2017003089A1 (es)
CO (1) CO2017012362A2 (es)
CR (1) CR20170540A (es)
CY (1) CY1122454T1 (es)
DK (1) DK3302565T3 (es)
DO (1) DOP2017000280A (es)
ES (1) ES2764459T3 (es)
HK (1) HK1250570A1 (es)
HR (1) HRP20192065T1 (es)
HU (1) HUE047477T2 (es)
IL (2) IL255632A (es)
LT (1) LT3302565T (es)
MX (2) MX376083B (es)
PE (1) PE20180395A1 (es)
PL (1) PL3302565T3 (es)
PT (1) PT3302565T (es)
RS (1) RS59672B1 (es)
RU (1) RU2686840C1 (es)
SA (1) SA517390473B1 (es)
SI (1) SI3302565T1 (es)
TW (2) TWI763881B (es)
WO (1) WO2016193860A1 (es)
ZA (1) ZA201707780B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
WO2017115315A1 (en) * 2015-12-30 2017-07-06 Dr. Reddy's Laboratories Limited Solid forms of palbociclib
CN105816437B (zh) * 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
CN108210454A (zh) * 2016-12-14 2018-06-29 深圳市华力康生物医药有限公司 一种帕布昔利布的口服乳剂及其制备方法
US20190381025A1 (en) * 2017-01-20 2019-12-19 Constellation Pharmaceuticals, Inc. Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
AU2018231044B2 (en) * 2017-03-08 2023-04-06 Cinrx Pharma, Llc Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
US20200054560A1 (en) * 2017-04-21 2020-02-20 Alnova Pharmaceuticals, Ltd. Palbociclib compositions and methods thereof
MX2019014201A (es) * 2017-05-31 2020-01-23 Boehringer Ingelheim Int Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas.
CN106970177B (zh) * 2017-06-06 2018-05-15 北京元延医药科技股份有限公司 帕博西尼中间体及其杂质的分析检测方法
MY200542A (en) 2017-07-10 2024-01-02 Takeda Pharmaceuticals Co Preparation comprising vonoprazan
EP3658119A1 (en) 2017-07-28 2020-06-03 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2019056163A1 (zh) * 2017-09-19 2019-03-28 浙江华海药业股份有限公司 N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法
CA3080197C (en) * 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
CN108014343A (zh) * 2017-12-21 2018-05-11 孟斯琴 一种治疗乳腺癌的药物组合物及其制备方法
CN108066303A (zh) * 2017-12-31 2018-05-25 湖南博隽生物医药有限公司 一种抗癌药物组合物及其制备方法
EP3758753A1 (en) 2018-02-27 2021-01-06 Pfizer Inc Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
ES2968899T3 (es) 2018-05-14 2024-05-14 Pfizer Formulación de la solución oral
CA3097594A1 (en) * 2018-05-15 2019-11-21 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pharmaceutical composition comprising small molecule egfr inhibitor and preparation method therefor
CN108653222A (zh) * 2018-07-03 2018-10-16 威海贯标信息科技有限公司 一种帕博西尼片剂组合物
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
CN109575021B (zh) * 2019-01-22 2020-09-18 北京海美桐医药科技有限公司 一种哌柏西利的制备方法
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
CA3136632A1 (en) * 2019-04-11 2020-10-15 Goldfinch Bio, Inc. Spray-dried formulation of a pyridazinone trpc5 inhibitor
EP4077325B1 (en) 2019-12-16 2026-03-11 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
IL293940B2 (en) 2019-12-16 2026-05-01 Lunella Biotech Inc Selective cancer drugs CDK4/6 inhibitors
CR20230018A (es) * 2020-06-19 2023-04-11 Acerta Pharma Bv Formas farmacéuticas de maleato de acalabrutinib
CN115989022A (zh) * 2020-07-02 2023-04-18 阿瑟姆治疗株式会社 口服用药物组合物及其制备方法
WO2022018596A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Combination therapy
CN114246872B (zh) * 2020-09-24 2024-02-06 南京济群医药科技股份有限公司 一种改善羟乙磺酸哌柏西利流动性的工艺方法及组合物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
EP4536233A4 (en) * 2022-06-08 2026-08-05 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL COMPOSITION INCLUDING PALBOCICLIB
EP4302755B1 (en) 2022-07-07 2025-08-20 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024258856A1 (en) * 2023-06-12 2024-12-19 Arvinas Operations, Inc. Solid oral dosage forms of estrogen receptor degraders
KR20250048897A (ko) 2023-10-04 2025-04-11 삼진제약주식회사 용해도 및 안정성이 개선된 팔보시클립을 포함하는 약학 조성물
KR102908668B1 (ko) * 2023-10-11 2026-01-06 경희대학교 산학협력단 화합물과 설폰산 또는 카르복시산의 결정체, 및 이를 포함하는 유방암 치료를 위한 약학적 조성물
KR20250062261A (ko) 2023-10-30 2025-05-08 신풍제약주식회사 향상된 용해도 및 안정성을 가지는 팔보시클립의 제약학적 조성물 및 이의 제조방법
WO2025156193A1 (en) * 2024-01-25 2025-07-31 Zhejiang Qizheng Pharmaceutical Co., Ltd. Palbociclib dosage form
WO2025226228A1 (en) * 2024-04-22 2025-10-30 Ilko Ilac Sanayi Ve Ticaret A.S. A novel formulation for palbociclib tablet
WO2026117542A1 (en) 2024-11-26 2026-06-04 Arvinas Operations, Inc. Combination therapy for the targeted degradation of bcl6

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE602004017474D1 (de) * 2003-07-11 2008-12-11 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
RU2442574C2 (ru) * 2005-08-22 2012-02-20 Новартис Аг ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ
US20070196491A1 (en) 2006-01-27 2007-08-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
KR20090052385A (ko) 2006-09-08 2009-05-25 화이자 프로덕츠 인크. 2-（피리딘-2-일아미노）-피리도［2,3-ｄ］피리미딘-7-온의합성
CA2663401C (en) 2006-09-15 2011-07-12 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
US9238571B2 (en) * 2009-09-30 2016-01-19 Merck Sharp & Dohme Limited Formulations for c-Met kinase inhibitors
RU2566716C2 (ru) 2010-06-09 2015-10-27 Эббви Бахамаз Лтд. Твердые дисперсии, содержащие ингибиторы киназ
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
CA2860098A1 (en) 2011-12-22 2013-06-27 Boehringer Ingelheim International Gmbh Immediate release multi unit pellet system
DK3431475T3 (da) 2013-02-21 2021-05-25 Pfizer Faste former af en selektiv CDK4/6-hæmmer
EP4772247A2 (en) 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
EA201690987A1 (ru) * 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN105816437B (zh) 2016-03-29 2018-08-03 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法

Also Published As

Publication number Publication date
WO2016193860A1 (en) 2016-12-08
JP2023112149A (ja) 2023-08-10
KR20200006633A (ko) 2020-01-20
AU2016272881C1 (en) 2019-10-03
HRP20192065T1 (hr) 2020-02-21
US20180207100A1 (en) 2018-07-26
AU2019204689B2 (en) 2020-12-03
EP3302565A1 (en) 2018-04-11
MX2020003825A (es) 2020-08-06
BR112017025398A2 (pt) 2018-08-07
LT3302565T (lt) 2019-12-27
CN107666914A (zh) 2018-02-06
CY1122454T1 (el) 2021-01-27
JP2021167343A (ja) 2021-10-21
AU2016272881B2 (en) 2019-04-11
JP2017002034A (ja) 2017-01-05
DK3302565T3 (da) 2020-01-02
JP7627302B2 (ja) 2025-02-05
SI3302565T1 (sl) 2020-02-28
ES2764459T3 (es) 2020-06-03
PT3302565T (pt) 2020-01-14
DOP2017000280A (es) 2018-01-15
CR20170540A (es) 2018-02-02
IL287437A (en) 2021-12-01
HK1250570A1 (zh) 2018-12-28
PL3302565T3 (pl) 2020-06-01
US11065250B2 (en) 2021-07-20
EP3636283A1 (en) 2020-04-15
AU2019204689A1 (en) 2019-07-18
HUE047477T2 (hu) 2020-04-28
TW201906611A (zh) 2019-02-16
EP3302565B1 (en) 2019-11-06
ZA201707780B (en) 2020-05-27
MX376083B (es) 2025-03-07
KR102068423B1 (ko) 2020-01-20
SA517390473B1 (ar) 2022-12-11
IL255632A (en) 2018-01-31
NZ737391A (en) 2023-11-24
US20210315900A1 (en) 2021-10-14
AU2016272881A1 (en) 2017-12-07
CA2931892A1 (en) 2016-12-04
TWI635863B (zh) 2018-09-21
TWI763881B (zh) 2022-05-11
TW201711687A (zh) 2017-04-01
RU2686840C1 (ru) 2019-05-06
CN113616606A (zh) 2021-11-09
KR102369405B1 (ko) 2022-03-02
RS59672B1 (sr) 2020-01-31
MX2017015579A (es) 2018-03-27
PE20180395A1 (es) 2018-02-28
KR20180015232A (ko) 2018-02-12
CO2017012362A2 (es) 2018-03-28

Similar Documents

Publication Publication Date Title
PE20180395A1 (es) Formas de dosificacion solidas de palbociclib
IL284577A (en) Gene therapy
EA201891211A1 (ru) Ингибиторы cxcr2
EP3393514A4 (en) KOVALENTE POLYMER ANTIGEN CONJUGATED PARTICLES
PL3769781T3 (pl) Stabilna formulacja anty-ifnar1
DK3295582T3 (da) Stråleformning
KR102494289B9 (ko) 활성 혼합물
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
CL2015003493S1 (es) Mueble.
DK3359555T3 (da) Doseringsplaner
EP3600279A4 (en) 1-amino-1-cyclopropanecaboxylic acid formulations
BR112017022691A2 (pt) inibidor de bromodomínio.
PL3226888T3 (pl) Podawanie selektywnego transsygnałowego inhibitora IL-6
DK3316856T3 (da) Blandede formuleringer
IL269169A (en) Novel dosage form
EP3634387C0 (en) DIAMOND DOSAGE FORM
ME03734B (me) KOMBINACIJA KANRENOATA I Ei&lt;SENATIDA
CL2016001698S1 (es) Reloj de arena
IL263085A (en) Gene therapy
EP3740063A4 (en) EPICHLOË-ENDOPHYTE
ECSP17085737A (es) Formas de dosificación sólidas de palbociclib
ITUB20159583A1 (it) Autocombustore di biomassa.
MA46864A (fr) Facteur vii inhibé par le site actif marqué par 177-lu
IT201700103032A1 (it) Moschettone
FR3037480B1 (fr) Melange herbicide